Latest news
{{'Fri, 20 Nov 2026 11:47:00 -0500' | dateFormatUsFilter}}
Novo’s Sogroya® receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner Syndrome (TS)
Read more
{{'Tue, 17 Nov 2026 08:00:00 -0500' | dateFormatUsFilter}}
Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
Read more
{{'Mon, 16 Nov 2026 17:00:00 -0500' | dateFormatUsFilter}}
Novo presents preclinical and human data suggesting a role for amylin and calcitonin receptor activation in preserving bone during weight loss at ObesityWeek®
Read more
Latest on compounded and counterfeit products and other important information about semaglutide.